Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 86 articles:
HTML format
Text format



Single Articles


    March 2017
  1. ZHANG Q, Chen WM, Zhang XX, Zhang HX, et al
    Overexpression of salusin-beta is associated with poor prognosis in ovarian cancer.
    Oncol Rep. 2017;37:1826-1832.
    PubMed     Text format     Abstract available


    January 2017
  2. GU G, Chen Y, Duan C, Zhou L, et al
    Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
    Oncol Rep. 2017 Jan 18. doi: 10.3892/or.2017.5388.
    PubMed     Text format     Abstract available


    November 2016
  3. LONG Q, Yang R, Lu W, Zhu W, et al
    Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells.
    Oncol Rep. 2016 Nov 21. doi: 10.3892/or.2016.5263.
    PubMed     Text format     Abstract available


  4. SHEN Y, Zhang XY, Chen X, Fan LL, et al
    Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
    Oncol Rep. 2016 Nov 18. doi: 10.3892/or.2016.5260.
    PubMed     Text format     Abstract available


    October 2016
  5. YE J, Chen W, Wu ZY, Zhang JH, et al
    Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5198.
    PubMed     Text format     Abstract available


  6. LI J, Huang H, Li Y, Li L, et al
    Decreased expression of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion, and indicates a poor prognosis in ovarian cancer.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5200.
    PubMed     Text format     Abstract available


  7. SANG XB, Sun KX, Wang LL, Chen S, et al
    Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis.
    Oncol Rep. 2016 Oct 11. doi: 10.3892/or.2016.5164.
    PubMed     Text format     Abstract available


  8. GUO P, Xiong X, Zhang S, Peng D, et al
    miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Oncol Rep. 2016 Oct 3. doi: 10.3892/or.2016.5140.
    PubMed     Text format     Abstract available


    September 2016
  9. ZHU Q, Wu X, Wu Y, Wang X, et al
    Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5136.
    PubMed     Text format     Abstract available


  10. LU W, Lu T, Wei X
    Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5134.
    PubMed     Text format     Abstract available


  11. MENG Y, Hu J, Chen Y, Yu T, et al
    Silencing MARCH1 suppresses proliferation, migration and invasion of ovarian cancer SKOV3 cells via downregulation of NF-kappaB and Wnt/beta-catenin pathways.
    Oncol Rep. 2016 Sep 8. doi: 10.3892/or.2016.5076.
    PubMed     Text format     Abstract available


    August 2016
  12. BI L, Yang Q, Yuan J, Miao Q, et al
    MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene.
    Oncol Rep. 2016 Aug 29. doi: 10.3892/or.2016.5055.
    PubMed     Text format     Abstract available


  13. LIN Z, Zhao J, Wang X, Zhu X, et al
    Overexpression of microRNA-497 suppresses cell proliferation and induces apoptosis through targeting paired box 2 in human ovarian cancer.
    Oncol Rep. 2016 Aug 11. doi: 10.3892/or.2016.5012.
    PubMed     Text format     Abstract available


  14. CHEN L, Zhang F, Sheng XG, Zhang SQ, et al
    MicroRNA-106a regulates phosphatase and tensin homologue expression and promotes the proliferation and invasion of ovarian cancer cells.
    Oncol Rep. 2016 Aug 9. doi: 10.3892/or.2016.5010.
    PubMed     Text format     Abstract available


    July 2016
  15. GONG C, Yang Z, Wu F, Han L, et al
    miR-17 inhibits ovarian cancer cell peritoneal metastasis by targeting ITGA5 and ITGB1.
    Oncol Rep. 2016 Jul 28. doi: 10.3892/or.2016.4985.
    PubMed     Text format     Abstract available


  16. ZHU L, Guo Q, Jin S, Feng H, et al
    Analysis of the gene expression profile in response to human epididymis protein 4 in epithelial ovarian cancer cells.
    Oncol Rep. 2016 Jul 11. doi: 10.3892/or.2016.4926.
    PubMed     Text format     Abstract available


    June 2016
  17. LI L, Duan Z, Yu J, Dang HX, et al
    NFATc1 regulates cell proliferation, migration, and invasion of ovarian cancer SKOV3 cells in vitro and in vivo.
    Oncol Rep. 2016 Jun 23. doi: 10.3892/or.2016.4904.
    PubMed     Text format     Abstract available


    May 2016
  18. CHE X, Yan H, Sun H, Dongol S, et al
    Grifolin induces autophagic cell death by inhibiting the Akt/mTOR/S6K pathway in human ovarian cancer cells.
    Oncol Rep. 2016 May 30. doi: 10.3892/or.2016.4840.
    PubMed     Text format     Abstract available


  19. SUNG HY, Han J, Ju W, Ahn JH, et al
    Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer.
    Oncol Rep. 2016 May 24. doi: 10.3892/or.2016.4835.
    PubMed     Text format     Abstract available


  20. WANG WJ, Sui H, Qi C, Li Q, et al
    Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1alpha in vitro.
    Oncol Rep. 2016 May 18. doi: 10.3892/or.2016.4813.
    PubMed     Text format     Abstract available


    April 2016
  21. ZHOU L, Xu T, Zhang Y, Zhu M, et al
    Transcriptional network in ovarian cancer cell line SKOV3 treated with Pinellia pedatisecta Schott extract.
    Oncol Rep. 2016 Apr 28. doi: 10.3892/or.2016.4779.
    PubMed     Text format     Abstract available


  22. LI Y, Wan X, Wei Y, Liu X, et al
    LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
    Oncol Rep. 2016 Apr 4. doi: 10.3892/or.2016.4729.
    PubMed     Text format     Abstract available


  23. UTSUMI F, Kajiyama H, Nakamura K, Tanaka H, et al
    Variable susceptibility of ovarian cancer cells to non-thermal plasma-activated medium.
    Oncol Rep. 2016 Apr 1. doi: 10.3892/or.2016.4726.
    PubMed     Text format     Abstract available


  24. DEVOR EJ, Schickling BM, Reyes HD, Warrier A, et al
    Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.
    Oncol Rep. 2016;35:2461-5.
    PubMed     Text format     Abstract available


  25. ELSNEROVA K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, et al
    Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma.
    Oncol Rep. 2016;35:2159-70.
    PubMed     Text format     Abstract available


    March 2016
  26. WANG YZ, Qiu SC
    Prediction of key genes in ovarian cancer treated with decitabine based on network strategy.
    Oncol Rep. 2016 Mar 23. doi: 10.3892/or.2016.4697.
    PubMed     Text format     Abstract available


  27. LU J, Zhang L, Xie F, Zhu L, et al
    Mild oxidative stress induced by a low dose of cisplatin contributes to the escape of TRAIL-mediated apoptosis in the ovarian cancer SKOV3 cell line.
    Oncol Rep. 2016 Mar 23. doi: 10.3892/or.2016.4702.
    PubMed     Text format     Abstract available


  28. YOSHIKAWA N, Kajiyama H, Nakamura K, Utsumi F, et al
    PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
    Oncol Rep. 2016 Mar 3. doi: 10.3892/or.2016.4653.
    PubMed     Text format     Abstract available


  29. YANG M, Xie X, Ding Y
    SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Oncol Rep. 2016;35:1796-806.
    PubMed     Text format     Abstract available


    February 2016
  30. SU M, Chang W, Zhang K, Cui M, et al
    Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.
    Oncol Rep. 2016;35:1179-1185.
    PubMed     Text format     Abstract available


  31. WENG Z, Gao H, Hu J, Fan Y, et al
    Isoalantolactone induces autophagic cell death in SKOV(3) human ovarian carcinoma cells via upregulation of PEA-15.
    Oncol Rep. 2016;35:833-40.
    PubMed     Text format     Abstract available


  32. TAKEDA T, Banno K, Okawa R, Yanokura M, et al
    ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Oncol Rep. 2016;35:607-13.
    PubMed     Text format     Abstract available


  33. ZOU Y, Deng W, Wang F, Yu XH, et al
    A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.
    Oncol Rep. 2016;35:725-30.
    PubMed     Text format     Abstract available


  34. KIM BR, Lee SH, Park MS, Seo SH, et al
    MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
    Oncol Rep. 2016;35:1041-8.
    PubMed     Text format     Abstract available


    January 2016
  35. HU C, Dong T, Li R, Lu J, et al
    Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3beta/beta-catenin/ZEB1 signaling pathway.
    Oncol Rep. 2016 Jan 25. doi: 10.3892/or.2016.4591.
    PubMed     Text format     Abstract available


  36. ZHANG R, Shi H, Ren F, Li X, et al
    Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Oncol Rep. 2016 Jan 21. doi: 10.3892/or.2016.4585.
    PubMed     Text format     Abstract available


  37. CHEN Q, Liu X, Xu L, Wang Y, et al
    Long non-coding RNA BACE1-AS is a novel target for anisomycin-mediated suppression of ovarian cancer stem cell proliferation and invasion.
    Oncol Rep. 2016 Jan 18. doi: 10.3892/or.2016.4571.
    PubMed     Text format     Abstract available


    December 2015
  38. LI J, Li D, Zhang W
    Tumor suppressor role of miR-217 in human epithelial ovarian cancer by targeting IGF1R.
    Oncol Rep. 2015 Dec 18. doi: 10.3892/or.2015.4498.
    PubMed     Text format     Abstract available


  39. GE G, Zhang W, Niu L, Yan Y, et al
    miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Oncol Rep. 2015 Dec 9. doi: 10.3892/or.2015.4482.
    PubMed     Text format     Abstract available


    November 2015
  40. SHEN YF, Wei AM, Kou Q, Zhu QY, et al
    Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
    Oncol Rep. 2015 Nov 16. doi: 10.3892/or.2015.4423.
    PubMed     Text format     Abstract available


  41. WANG L, Niu CH, Wu S, Wu HM, et al
    PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells.
    Oncol Rep. 2015 Nov 4. doi: 10.3892/or.2015.4396.
    PubMed     Text format     Abstract available


  42. DENG Z, Zhou J, Han X, Li X, et al
    TCEB2 confers resistance to VEGFtargeted therapy in ovarian cancer.
    Oncol Rep. 2015 Nov 3. doi: 10.3892/or.2015.4388.
    PubMed     Text format     Abstract available


  43. SZCZERBA A, Sliwa A, Kubiczak M, Nowak-Markwitz E, et al
    Human chorionic gonadotropin beta subunit affects the expression of apoptosis-regulating factors in ovarian cancer.
    Oncol Rep. 2015 Nov 3. doi: 10.3892/or.2015.4386.
    PubMed     Text format     Abstract available


  44. SEINO M, Okada M, Sakaki H, Takeda H, et al
    Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
    Oncol Rep. 2015 Nov 2. doi: 10.3892/or.2015.4377.
    PubMed     Text format     Abstract available


  45. SU M, Fan C, Gao S, Shen A, et al
    An HCG-rich microenvironment contributes to ovarian cancer cell differentiation into endothelioid cells in a three-dimensional culture system.
    Oncol Rep. 2015;34:2395-402.
    PubMed     Text format     Abstract available


    October 2015
  46. ZHANG D, Qiu S, Wang Q, Zheng J, et al
    TMPRSS3 modulates ovarian cancer cell proliferation, invasion and metastasis.
    Oncol Rep. 2015 Oct 29. doi: 10.3892/or.2015.4356.
    PubMed     Text format     Abstract available


  47. HE Z, Chen AY, Rojanasakul Y, Rankin GO, et al
    Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1alpha/VEGF signaling pathway in ovarian cancer cells.
    Oncol Rep. 2015 Oct 27. doi: 10.3892/or.2015.4354.
    PubMed     Text format     Abstract available


  48. ZOU W, Ma X, Hua W, Chen B, et al
    Caveolin-1 mediates chemoresistance in cisplatinresistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-kappaB pathway.
    Oncol Rep. 2015 Oct 1. doi: 10.3892/or.2015.4320.
    PubMed     Text format     Abstract available


  49. GAO J, Liu M, Zou Y, Mao M, et al
    Long non-coding RNA growth arrest-specific transcript 5 is involved in ovarian cancer cell apoptosis through the mitochondria-mediated apoptosis pathway.
    Oncol Rep. 2015 Oct 1. doi: 10.3892/or.2015.4318.
    PubMed     Text format     Abstract available


    September 2015
  50. XU Y, Wang C, Su J, Xie Q, et al
    Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis.
    Oncol Rep. 2015 Sep 17. doi: 10.3892/or.2015.4283.
    PubMed     Text format     Abstract available


    August 2015
  51. ZHANG J, Wang W, Qian L, Zhang Q, et al
    Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
    Oncol Rep. 2015 Aug 20. doi: 10.3892/or.2015.4213.
    PubMed     Text format     Abstract available


  52. HU L, Cong L
    Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
    Oncol Rep. 2015 Aug 20. doi: 10.3892/or.2015.4212.
    PubMed     Text format     Abstract available


  53. YAN S, Yuan C, Yang Q, Li X, et al
    A genetic polymorphism (rs17251221) in the calcium-sensing receptor is associated with ovarian cancer susceptibility.
    Oncol Rep. 2015 Aug 5. doi: 10.3892/or.2015.4179.
    PubMed     Text format     Abstract available


    July 2015
  54. SU M, Chang W, Wang D, Cui M, et al
    Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
    Oncol Rep. 2015 Jul 9. doi: 10.3892/or.2015.4118.
    PubMed     Text format     Abstract available


  55. WU J, Lai M, Shao C, Wang J, et al
    STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
    Oncol Rep. 2015 Jul 9. doi: 10.3892/or.2015.4120.
    PubMed     Text format     Abstract available


  56. ZHANG HY, Li JH, Li G, Wang SR, et al
    Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer.
    Oncol Rep. 2015 Jul 7. doi: 10.3892/or.2015.4113.
    PubMed     Text format     Abstract available


    June 2015
  57. ALTHAWADI H, Alfarsi H, Besbes S, Mirshahi S, et al
    Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.
    Oncol Rep. 2015 Jun 15. doi: 10.3892/or.2015.4061.
    PubMed     Text format     Abstract available


  58. YANG C, He X, Liu X, Tang Z, et al
    OSTP as a novel peptide specifically targeting human ovarian cancer.
    Oncol Rep. 2015 Jun 15. doi: 10.3892/or.2015.4066.
    PubMed     Text format     Abstract available


  59. DONG Y, Li J, Han F, Chen H, et al
    High IGF2 expression is associated with poor clinical outcome in human ovarian cancer.
    Oncol Rep. 2015 Jun 10. doi: 10.3892/or.2015.4048.
    PubMed     Text format     Abstract available


  60. ZHOU J, Gong G, Tan H, Dai F, et al
    Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
    Oncol Rep. 2015;33:2915-23.
    PubMed     Text format     Abstract available


  61. DONG R, Jin C, Zhang Q, Yang X, et al
    Cellular leiomyoma with necrosis and mucinous degeneration presenting as pseudo-Meigs' syndrome with elevated CA125.
    Oncol Rep. 2015;33:3033-7.
    PubMed     Text format     Abstract available


    May 2015
  62. WANG X, Jiang W, Kang J, Liu Q, et al
    Knockdown of RhoA expression alters ovarian cancer biological behavior in vitro and in nude mice.
    Oncol Rep. 2015 May 28. doi: 10.3892/or.2015.4009.
    PubMed     Text format     Abstract available


  63. ZHAO J, Ye W, Wu J, Liu L, et al
    Sp1-CD147 positive feedback loop promotes the invasion ability of ovarian cancer.
    Oncol Rep. 2015 May 20. doi: 10.3892/or.2015.3999.
    PubMed     Text format     Abstract available


  64. MAYER S, Hirschfeld M, Jaeger M, Pies S, et al
    RON alternative splicing regulation in primary ovarian cancer.
    Oncol Rep. 2015 May 19. doi: 10.3892/or.2015.3995.
    PubMed     Text format     Abstract available


  65. ZHOU J, Xie M, Shi Y, Luo B, et al
    MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.
    Oncol Rep. 2015 May 5. doi: 10.3892/or.2015.3952.
    PubMed     Text format     Abstract available


  66. HABATA S, Iwasaki M, Sugio A, Suzuki M, et al
    BAG3 increases the invasiveness of uterine corpus carcinoma cells by suppressing miR-29b and enhancing MMP2 expression.
    Oncol Rep. 2015;33:2613-21.
    PubMed     Text format     Abstract available


    April 2015
  67. GUO J, Chen L, Luo N, Yang W, et al
    Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.
    Oncol Rep. 2015 Apr 7. doi: 10.3892/or.2015.3902.
    PubMed     Text format     Abstract available


  68. LI J, Jiang K, Zhao F
    Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2.
    Oncol Rep. 2015 Apr 1. doi: 10.3892/or.2015.3891.
    PubMed     Text format     Abstract available


    March 2015
  69. YANG M, Zou J, Zhu H, Liu S, et al
    Paris saponin II inhibits human ovarian cancer cellinduced angiogenesis by modulating NF-kappaB signaling.
    Oncol Rep. 2015 Mar 5. doi: 10.3892/or.2015.3836.
    PubMed     Text format     Abstract available


  70. XU J, Yong M, Li J, Dong X, et al
    High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo.
    Oncol Rep. 2015 Mar 3. doi: 10.3892/or.2015.3829.
    PubMed     Text format     Abstract available


    February 2015
  71. BROZYNA AA, Jozwicki W, Jochymski C, Slominski AT, et al
    Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas.
    Oncol Rep. 2015;33:599-606.
    PubMed     Text format     Abstract available


    January 2015
  72. TANG Z, Zhang N, Di W, Li W, et al
    Inhibition of microtubule-associated protein 1 light chain 3B via small-interfering RNA or 3-methyladenine impairs hypoxia-induced HO8910PM and HO8910 epithelial ovarian cancer cell migration and invasion and is associated with RhoA and alterations of
    Oncol Rep. 2015 Jan 20. doi: 10.3892/or.2015.3742.
    PubMed     Text format     Abstract available


  73. ZHANG R, Shi H, Ren F, Liu H, et al
    Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Oncol Rep. 2015 Jan 15. doi: 10.3892/or.2015.3723.
    PubMed     Text format     Abstract available


    December 2014
  74. LIU T, Liu P, Ding F, Yu N, et al
    Ampelopsin reduces the migration and invasion of ovarian cancer cells via inhibition of epithelial-to-mesenchymal transition.
    Oncol Rep. 2014 Dec 12. doi: 10.3892/or.2014.3672.
    PubMed     Text format     Abstract available


  75. CAI M, Hu Z, Liu J, Gao J, et al
    Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis.
    Oncol Rep. 2014 Dec 5. doi: 10.3892/or.2014.3649.
    PubMed     Text format     Abstract available


  76. ZHAO H, Liu S, Wang G, Wu X, et al
    Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
    Oncol Rep. 2014 Dec 2. doi: 10.3892/or.2014.3640.
    PubMed     Text format     Abstract available


    November 2014
  77. PAN Y, Zhang L, Zhang X, Liu R, et al
    Synergistic effects of eukaryotic co-expression plasmid-based STAT3-specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.
    Oncol Rep. 2014 Nov 25. doi: 10.3892/or.2014.3623.
    PubMed     Text format     Abstract available


  78. MA X, Duan H, Liu J, Mo Q, et al
    Effect of LIV1 on the sensitivity of ovarian cancer cells to trichostatin A.
    Oncol Rep. 2014 Nov 25. doi: 10.3892/or.2014.3622.
    PubMed     Text format     Abstract available


  79. JI M, Shi H, Xie Y, Zhao Z, et al
    Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor beta1.
    Oncol Rep. 2014 Nov 3. doi: 10.3892/or.2014.3580.
    PubMed     Text format     Abstract available


    August 2014
  80. OISHI T, Itamochi H, Kudoh A, Nonaka M, et al
    The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oncol Rep. 2014;32:553-8.
    PubMed     Text format     Abstract available


  81. AMABLE L, Fain J, Gavin E, Reed E, et al
    Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug.
    Oncol Rep. 2014;32:469-74.
    PubMed     Text format     Abstract available


    July 2014
  82. SONG Y, Xin X, Xia Z, Zhai X, et al
    Selective suppression of autocatalytic caspase-3 driven by two-step transcriptional amplified human telomerase reverse transcriptase promoter on ovarian carcinoma growth in vitro and in mice.
    Oncol Rep. 2014;32:225-34.
    PubMed     Text format     Abstract available


  83. KANG KW, Lee MJ, Song JA, Jeong JY, et al
    Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma.
    Oncol Rep. 2014;32:189-98.
    PubMed     Text format     Abstract available


    June 2014
  84. YANG Y, Ma B, Li L, Jin Y, et al
    CDK2 and CDK4 play important roles in promoting the proliferation of SKOV3 ovarian carcinoma cells induced by tumor-associated macrophages.
    Oncol Rep. 2014;31:2759-68.
    PubMed     Text format     Abstract available


    May 2014
  85. GUO F, Cogdell D, Hu L, Yang D, et al
    MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.
    Oncol Rep. 2014;31:2021-8.
    PubMed     Text format     Abstract available


  86. BERRETTA R, Patrelli TS, Migliavacca C, Rolla M, et al
    Assessment of tumor size as a useful marker for the surgical staging of endometrial cancer.
    Oncol Rep. 2014;31:2407-12.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: